Expression and clinical significance of lysophosphatidic acid receptor 5 protein in breast cancer
10.3760/cma.j.issn.1008-6706.2020.02.020
- VernacularTitle: 溶血磷脂酸受体5在乳腺癌组织中的表达及临床意义
- Author:
Juan ZHENG
1
;
Yuancheng XU
1
;
Xingyuan ZHOU
1
Author Information
1. Department of Pathology, the First People's Hospital of Yongkang, Yongkang, Zhejiang 321300, China
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Immunohistochemistry;
Receptors, lysophosphatidic acid;
Prognosis;
Staging;
Lymph node metastasis;
Survival
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(2):213-217
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression and clinical significance of lysophosphatidic acid receptor 5 (LPA5) protein in breast cancer tissues.
Methods:The specimens of breast cancer tissues and adjacent tissues of 80 breast cancer patients from January 2015 to December 2016 in the First People's Hospital of Yongkang were selected in the study.The expression of LPA5 in breast cancer tissues and adjacent tissues was determined by immunohistochemistry.The clinical case characteristics of patients were collected.
Results:The positive expression rate of LPA5 in breast cancer tissues(72.5%) was higher than that in adjacent tissues(8.75%)(χ2=67.394, P<0.05). The positive rate of LPA5 in clinical stage Ⅲ-Ⅳ(91.3%) was higher than that in stage Ⅰ-Ⅱ(64.9%)(χ2=5.725, P<0.05). The positive rate of LPA5 in patients with lymph node metastasis(94.7%) was higher than that in patients without lymph node metastasis(52.4%)(χ2=17.951, P<0.05). The positive rate of LPA5 in patients with intravascular tumor thrombus(92.3%) was higher than that in patients without intravascular tumor thrombus (63.3%)(χ2=7.580, P<0.05). The expression of LPA5 in breast cancer tissues was not related to age and tumor diameter (P>0.05). There were no significant differences in the positive expression rates of LPA5 in the breast cancer tissues among luminal type, human epidermal growth factor receptor 2 (Her2) overexpressing type and triple negative type (P>0.05). The disease-free survival rate(86.3%) and overall survival rate(87.5%) of patients with negative expression of LPA5 in breast cancer tissues were higher than those in breast cancer tissues with positive expression (65.0%, 66.3%)(χ2=4.517, 4.328, all P<0.05).
Conclusion:LPA5 expression is up-regulated in breast cancer tissues, and LPA5 may be involved in the development and progression of breast cancer, which is closely related to the prognosis of breast cancer.
